Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Don Walster who wrote (234)	11/22/1998 5:43:00 PM
From: Zvi Steinberg	Read Replies (1) \| Respond to of 1386

Market Edge - weekly second opinion rates PARS as Buy: COMMENT Moving Average Convergence/Divergence (MACD) indicates a BULLISH TREND Chart pattern indicates a WEAK UPWARD TREND Relative Strength is BEARISH Up/Down volume pattern indicates that the stock is under ACCUMULATION The 50 day MOVING AVERAGE is rising which is BULLISH The 200 day MOVING AVERAGE is rising which is BULLISH LOOK FOR SUPPORT AT 1.66 RECOMMENDATION STOCK IS A BUY MarketEdge & Second Opinion are neither offers to sell nor solictations of offers to buy any security. For what it's worth. Zvi

To: Don Walster who wrote (234)	11/22/1998 9:51:00 PM
From: Gabe Fernandez	Read Replies (1) \| Respond to of 1386

Don you are probably right physicians tend to write in more technical terms and that is an error in our part,in my posts especially in Yahoo i tried to make my technical opinions easier to understand. What i meant to discuss with Ariella was that Hu-211 in the discussions now have been more in the field of neurosurgeons since they are the ones who treat TBI. Neurologists in the future will have to do the studies in STROKES,Alzheimers and other degenerative diseases of the brain. I will dare say that 90% of neurologists are not aware of HU-211 studies but most neurosurgeons that attended the meeting in Seattle are aware of the same.